1103738-30-2

Basic information

• Product Name: D-xylo-Pentodialdo-5,2-furanose, 1-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-4,5-O-(1-Methylethylidene)-,(5S)-
• Synonyms: D-xylo-Pentodialdo-5,2-furanose, 1-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-4,5-O-(1-Methylethylidene)-,(5S)-;(4-chloro-3-(4-ethoxybenzyl)phenyl)((3aS,5R,6S,6aS)-6-hydroxy-2,2-diMethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)Methanone;(4-chloro-3-(4-ethoxybenzyl)phenyl)((5R,6S)-6-hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methanone;(4-Chloro-3-(4-ethoxybenzyl)phenyl)((3aS,5R,6S,6aS)-6- hydroxy-2,2-dimethyltetrahydrofuro[3,2-d][1,3]dioxol- 5-yl)methanone;EOS-61382;(4-chloro-3-(4-ethoxybenzyl)phenyl)((3aS,5R,6S,6aS)-6-hydroxy-;(5S)-1-C-[4-Chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-4,5-O-(1-methylethylidene)-D-xylo-pentodialdo-5,2-furanose;(5S)-1-C-[4-Chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-4,5-O-(1-methylethylidene)-D-xylo-pentodialdo-5,2-furanose
• CAS NO: 1103738-30-2
• Molecular Formula: C₂₃H₂₅ClO₆
• Molecular Weight: 432.894
• Mol File: 1103738-30-2.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 601.7±55.0 °C(Predicted)
• Appearance: /
• Density: 1.271±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 12?+-.0.60(Predicted)
• CAS DataBase Reference: D-xylo-Pentodialdo-5,2-furanose, 1-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-4,5-O-(1-Methylethylidene)-,(5S)-(CAS DataBase Reference)
• NIST Chemistry Reference: D-xylo-Pentodialdo-5,2-furanose, 1-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-4,5-O-(1-Methylethylidene)-,(5S)-(1103738-30-2)
• EPA Substance Registry System: D-xylo-Pentodialdo-5,2-furanose, 1-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-4,5-O-(1-Methylethylidene)-,(5S)-(1103738-30-2)

Safety Data

• Hazardous Substances Data: 1103738-30-2(Hazardous Substances Data)

Usage

General Description

D-Xylo-Pentodialdo-5,2-furanose, 1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-4,5-O-(1-methylethylidene)-,(5S)-is a chemical compound that is a derivative of xylo-pentodialdo-furanose. It contains a 1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-4,5-O-(1-methylethylidene) group, and it has a stereochemistry of (5S). D-xylo-Pentodialdo-5,2-furanose, 1-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-4,5-O-(1-Methylethylidene)-,(5S)- has potential applications in the field of pharmaceuticals and may be used in the development of new drugs or as a reference compound in research.

Upstream product

• 1103738-29-9 1-chloro-2-(4-ethoxybenzyl)-4-iodobenzene 
• 1103738-19-7 ((3aS,5R,6S,6aS)-6-hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)(morpholin-4-yl)methanone 
• 1068-55-9 isopropylmagnesium chloride 
• 1103738-20-0 morpholine (3aS,5R,6S,6aS)-6-hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxole-5-carboxylic acid 
• 1103738-26-6 (2-chloro-5-iodo-phenyl)-(4-ethoxyphenyl)methanone 
• 1103738-17-5 (3aS,5R,6S,6aS)-6-hydroxy-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxolane-5-carboxylic acid 
• 114861-22-2 1,2-O-isopropylidene-α-L-xylofuranose 
• 609-06-3 L-xylose 
• 19094-56-5 2-chloro-5-iodobenzoic acid 
• 281652-58-2 2-chloro-5-iodobenzoylchloride 
• 677-22-5 tert-butylmagnesium chloride 
• 108-21-4 Isopropyl acetate 
• 461432-22-4 (5-bromo-2-chlorophenyl)(4-ethyloxyphenyl)methanone 
• 21900-52-7 5-bromo-2-chloro-benzoyl chloride 

Downstream Products

• 1103738-34-6 (3aS,5S,6R,6aS)-5-((R)-(4-chloro-3-(4-ethoxybenzyl)phenyl)(hydroxy)methyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-6-ol 
• 1018899-04-1 (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(methylsulfanyl)tetrahydro-2-H-pyran-3,4,5-triol 
• 1018899-03-0 [(2S,3S,4R,5S,6R)-4,5-diacetoxy-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylthiotetrahydropyran-3-yl]acetate 
• 1018898-84-4 acetic acid (3S,4R,5S,6S)-2,4,5-triacetoxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-tetrahydropyran-3-yl ester 
• 1192136-41-6 (5R,6R)-5-((S)-1-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxyethyl)-2,2-dimethyltetrahydrofuro-[2,3-d][1,3]dioxol-6-ol 

Relevant articles and documents

Process development of sotagliflozin, a dual inhibitor of sodium- Glucose cotransporter-1/2 for the treatment of diabetes

The development of an efficient manufacturing process for sotagliflozin (LX4211), a dual inhibitor of sodium- glucose cotransporter-1/2 (SGLT-1/2) for the treatment of diabetes, is described. Sotagliflozin features five contiguous chiral centers on the carbohydrate core flanked by a thioether group and a biaryl moiety. Three chiral centers are obtained from the starting material L-xylose, while the other two were established (or modified) via three highly stereoselective transformations: Luche reduction (dr: 97/3), dynamic kinetic resolution of anomeric hemiacetal (dr: 95/5), and Lewis acid-promoted thiolation (dr: 1000/ 1). Global deprotection of the resulting penultimate intermediate with catalytic sodium methoxide followed by recrystallization furnishes sotagliflozin. The longest linear sequence consists of 10 steps from L-xylose with an overall yield of 40%. This process has been performed on multi-hundred kilogram batches to satisfy the drug substance development demands.

COMPOSITIONS COMPRISING (2S,3R,4R,5S,6R)-2-(4- CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL

Pharmaceutical dosage forms useful for improving the cardiovascular and/or metabolic health of patients, particularly those suffering from type 2 diabetes, are disclosed, as well as methods of their manufacture.

Solid forms of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol and methods of their use

Solid forms of anhydrous (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol are disclosed, in addition to methods of their use in the treatment of various diseases and disorders.